Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Cancer Research

• Publication date

  1999-06-15

• Fields of study

  Medicine

• Identifiers
  PMID 10383159
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.

  2000cited by this paper
• Eradication of Minimal Disease in Severe Combined Immunodeficient Mice With Disseminated Daudi Lymphoma Using Chemotherapy and an Immunotoxin Cocktail

  2000cited by this paper
• Cell specific cytotoxicity and structure-activity relationship of lipophilic 1-B-D-arabinofuranosylcytosine (ara-C) derivatives.

  1999cited by this paper
• New antimetabolites in cancer chemotherapy and their clinical impact.

  1998cited by this paper
• Combined Carboplatin and Cytosine Arabinoside in Metastatic Melanoma Refractory to Dacarbazine

  1995cited by this paper
• Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.

  1994cited by this paper
• Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study.

  1994cited by this paper
• Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail.

  1994cited by this paper
• Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study.

  1993cited by this paper
• Extended CSF cytarabine exposure following intrathecal administration of DTC 101.

  1993cited by this paper
• The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.

  1993cited by this paper
• Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis.

  1993cited by this paper
• Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam.

  1993cited by this paper
• A study of the delivery-targeting concept applied to antineoplasic drugs active on human osteosarcoma. I. Synthesis and biological activity in nude mice carrying human osteosarcoma xenografts of gem-bisphosphonic methotrexate analogues

  1992cited by this paper
• Immunotoxins directed against the high‐molecular‐weight melanoma‐associated antigen. Identification of potent antibody‐toxin combinations

  1992cited by this paper
• Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.

  1992cited by this paper
• Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer.

  1991cited by this paper
• Practical spontaneous metastasis model for in vivo therapeutic studies using a human melanoma.

  1991cited by this paper
• Carboplatinum and cytosine arabinoside in patients with disseminated malignant melanoma

  1991cited by this paper
• Cytarabine and neurologic toxicity.

  1991cited by this paper
• Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro

  1991cited by this paper
• A new experimental metastasis model in athymic nude mice, the human malignant melanoma lox

  1988cited by this paper
• Preclinical phase II studies in human tumor lines: a European multicenter study.

  1988cited by this paper
• Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development (review).

  1987cited by this paper
• Human melanoma cell lines showing striking inherent differences in sensitivity to immunotoxins containing holotoxins.

  1986cited by this paper
• Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma

  1986cited by this paper
• Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma.

  1985cited by this paper
• Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas.

  1985cited by this paper
• Cytosine arabinoside influx and nucleoside transport sites in acute leukemia.

  1982cited by this paper
• Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization

  1978cited by this paper
• Classification and biological nature of established human hematopoietic cell lines

  1975influential reference
• Terminal deoxynucleotidyl transferase activity in a cell line (molt-4) derived from the peripheral blood of a patient with acute lymphoblastic leukemia.

  1973cited by this paper
• Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji).

  1966influential reference

• Effects of nucleoside analogues, lipophilic prodrugs and elaidic acids on core signaling pathways in cancer cells

  2024cites this paper
• Opportunities and Challenges of Fatty Acid Conjugated Therapeutics.

  2021cites this paper
• A review on gemcitabine modification

  2020cites this paper
• Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.

  2020cites this paper
• Emerging insights on drug delivery by fatty acid mediated synthesis of lipophilic prodrugs as novel nanomedicines.

  2020cites this paper
• Metabolism of bioconjugate therapeutics: why, when, and how?

  2020cites this paper
• Anticancer activities of fatty acids and their heterocyclic derivatives.

  2020cites this paper
• DNA Methylation: Biological Implications and Modulation of Its Aberrant Dysregulation

  2019cites this paper
• GSH responsive nanomedicines self-assembled from small molecule prodrug alleviate the toxicity of cardiac glycosides as potent cancer drugs.

  2019cites this paper
• A preclinical evaluation of cytarabine prodrug nanofibers assembled from cytarabine‐lauric acid conjugate toward solid tumors

  2018cites this paper
• Chemotherapy agent‐unsaturated fatty acid prodrugs and prodrug‐nanoplatforms for cancer chemotherapy

  2017cites this paper
• Transporter-targeted cholic acid-cytarabine conjugates for improved oral absorption.

  2016cites this paper
• mproving nucleoside analogs via lipid conjugation : Is fatter any etter ?

  2016cites this paper
• Improving nucleoside analogs via lipid conjugation: Is fatter any better?

  2016cites this paper
• Lipid-Based Carriers for Prodrugs to Enhance Delivery

  2015cites this paper
• Biocatalytic approaches applied to the synthesis of nucleoside prodrugs.

  2015cites this paper
• Clinical potential of elacytarabine in patients with acute myeloid leukemia

  2014cites this paper
• In vitro antiproliferative and antimicrobial evaluation of Kigelia pinnata

  2014cites this paper
• Lipid-Based Drug Carriers for Prodrugs to Enhance Drug Delivery

  2014cites this paper
• International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.

  2014cites this paper
• Designer lipids for drug delivery: from heads to tails.

  2014cites this paper
• Synthesis and initial biological evaluation of substituted 1-phenylamino-2-thio-4,5-dimethyl-1H-imidazole derivatives.

  2013cites this paper
• Synthesis, characterization, and in vitro evaluation of two synergistic anticancer drug-containing hepatoma-targeting micelles formed from amphiphilic random copolymer.

  2013cites this paper
• Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications.

  2013cites this paper
• Gemcitabine versus modified gemcitabine : a review of several promising chemical modifications

  2013cites this paper
• Glucose-functionalized multidrug-conjugating nanoparticles based on amphiphilic terpolymer with enhanced anti-tumorous cell cytotoxicity.

  2013cites this paper
• Developmental Therapeutics in Acute Myelogenous Leukemia: Are There Any New Effective Cytotoxic Chemotherapeutic Agents Out There?

  2013cites this paper
• Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia

  2013cites this paper
• Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.

  2013cites this paper
• Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts.

  2013cites this paper
• Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases

  2013cites this paper
• Using Drosophila melanogaster as a Whole-Model Animal System to Elucidate the Mechanism of Action of Novel Anticancer Agents

  2012cites this paper
• Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia

  2012cites this paper
• Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.

  2012cites this paper
• EORTC-related new drug discovery and development activities: role of the Pharmacology and Molecular Mechanisms Group

  2012cites this paper
• Elacytarabine — A New Agent in the Treatment of Relapsed/Refractory Acute Myeloid Leukaemia

  2012cites this paper
• Elacytarabine has single‐agent activity in patients 
with advanced acute myeloid leukaemia

  2012cites this paper
• Elacytarabine – lipid vector technology overcoming drug resistance in acute myeloid leukemia

  2011cites this paper
• Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

  2011cites this paper
• Lipophilic Prodrugs and Formulations of Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer

  2011cites this paper
• A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy

  2011cites this paper
• Prodrug-based intracellular delivery of anticancer agents.

  2011cites this paper
• Molecular Cancer apeutics linical Development ercept Exerts Antivascular Effects and Enhances Levels nthracycline Chemotherapy In vivo in Human Ther te Myeloid Leukemia Models

  2010cites this paper
• The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside Analogues

  2010cites this paper
• Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models

  2010influential citation
• Development of cytarabine prodrugs and delivery systems for leukemia treatment

  2010cites this paper
• Induction of Resistance to the Lipophilic Cytarabine Prodrug Elacytarabine (CP-4055) in CEM Leukemic Cells

  2010cites this paper
• Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy In vivo in Human Acute Myeloid Leukemia Models

  2010cites this paper
• Delivery of 5-Azacytidine to Human Cancer Cells by Elaidic Acid Esterification Increases Therapeutic Drug Efficacy

  2010cites this paper
• Synthesis and evaluation of fatty acyl ester derivatives of cytarabine as anti-leukemia agents.

  2010cites this paper
• Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential.

  2010cites this paper
• Multidrug nanoparticles based on novel random copolymer containing cytarabine and fluorodeoxyuridine.

  2010cites this paper
• Lipid-Based Anticancer Prodrugs

  2010cites this paper
• Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel.

  2009cites this paper
• Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study

  2009cites this paper
• CP‐4055 and CP‐4126 are active in ara‐C and gemcitabine‐resistant lymphoma cell lines

  2009cites this paper
• Innovations and opportunities to improve conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer.

  2009cites this paper
• Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine

  2009cites this paper
• Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy.

  2008cites this paper
• Recent trends in targeted anticancer prodrug and conjugate design.

  2008cites this paper
• Anti proliferative activity of ELACYT™ (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells

  2008cites this paper
• Preparation of potential 3-deazauridine and 6-azauridine prodrugs through an enzymatic alcoholysis

  2007cites this paper
• Review of recent studies on resistance to cytotoxic deoxynucleoside analogues.

  2007cites this paper
• Recent developments to improve the efficacy of cytotoxic nucleoside analogues.

  2006cites this paper
• Fatty acid patterns of waste parts of Turkish Pistacia vera L. tree

  2006cites this paper
• Synthesis and biological activity of some new 5'-O-acyl tiazofurin derivatives.

  2006cites this paper
• Controllable selective synthesis of a polymerizable prodrug of cytarabine by enzymatic and chemical methods.

  2005cites this paper
• Animal models of leptomeningeal cancer.

  2005cites this paper
• Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.

  2004cites this paper
• NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS

  2004cites this paper
• Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug.

  2004cites this paper
• Prodrug strategies in cancer therapy.

  2001cites this paper